EN
抗体药类似物
Research Grade Vudalimab
All
  • CatalogTD-HS870226
  • ClonalitymAb
  • Application Research Grade Biosimilar
  • SynonymsBispecific,XmAb-20717,XMAB20717,CAS:2329669-72-7
  • 规格
    1mg
  • 价格
    ¥询价
定制服务咨询

Research Grade Vudalimab


Catalog No. TD-HS870226
Species reactivity Human
Applications Research Grade Biosimilar
Host species Humanized
Isotype half-IGG1-kappa/(scFv-kappa-heavy)-h-CH2-CH3
Expression system Mammalian Cells
Clonality Monoclonal
Target Programmed cell death protein 1, Protein PD-1, hPD-1, PD1, PDCD1, CD279, CD152, Cytotoxic T-lymphocyte protein 4, CTLA-4, CTLA4, Cytotoxic T-lymphocyte-associated antigen 4
Endotoxin level Please contact the lab for this information.
Purity >95% purity as determined by SDS-PAGE.
Purification Protein A/G, purified from cell culture supernatant.
Accession Q15116 & P16410
Form Liquid
Storage buffer 0.01M PBS,pH7.4.
Stability and Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
Alternate Names Bispecific,XmAb-20717,XMAB20717,CAS:2329669-72-7
Background Vudalimab is a potent dual PD-1 and CTLA-4 inhibitor as a fully humanized bispecific monoclonal antibody. Vudalimab targets immune checkpoint receptors PD-1 and CTLA-4 and promotes tumor-selective T-cell activation.
Note For research use only. Not for use in clinical or therapeutic applications

 

TD-HS870226_1.jpg
Bioactivity
 
Detects CD279/PDCD1/PD1 in indirect ELISAs.